Literature DB >> 12904059

Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein.

Martin Vogtherr1, Susanne Grimme, Bettina Elshorst, Doris M Jacobs, Klaus Fiebig, Christian Griesinger, Ralph Zahn.   

Abstract

Using NMR spectroscopy we show that the cellular prion protein constitutes a target for binding of various acridine and phenothiazine derivatives. We unambiguously map the quinacrine binding site of recombinant human prion protein to residues Tyr225, Tyr226, and Gln227 of helix alpha3, which is located near the "protein X" epitope. The millimolar dissociation constant of the complex suggests that in vivo inhibition of prion propagation occurs after 10000-fold concentration of quinacrine within endolysosomes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904059     DOI: 10.1021/jm034093h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

Review 1.  Antiprion drugs as chemical tools to uncover mechanisms of prion propagation.

Authors:  Déborah Tribouillard; Fabienne Gug; Hervé Galons; Stéphane Bach; Sven J Saupe; Marc Blondel
Journal:  Prion       Date:  2007-01-20       Impact factor: 3.931

2.  Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.

Authors:  Junji Hosokawa-Muto; Yuji O Kamatari; Hironori K Nakamura; Kazuo Kuwata
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

3.  Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.

Authors:  Michael D Geschwind; Amy L Kuo; Katherine S Wong; Aissa Haman; Gillian Devereux; Benjamin J Raudabaugh; David Y Johnson; Charles C Torres-Chae; Ron Finley; Paul Garcia; Julie N Thai; Hugo Q Cheng; John M Neuhaus; Sven A Forner; Jacque L Duncan; Katherine L Possin; Stephen J Dearmond; Stanley B Prusiner; Bruce L Miller
Journal:  Neurology       Date:  2013-10-11       Impact factor: 9.910

4.  A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets.

Authors:  Guillaume Poncet-Montange; Susan J St Martin; Olga V Bogatova; Stanley B Prusiner; Brian K Shoichet; Sina Ghaemmaghami
Journal:  J Biol Chem       Date:  2011-05-24       Impact factor: 5.157

5.  A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie.

Authors:  Véronique Gayrard; Nicole Picard-Hagen; Catherine Viguié; Valerie Laroute; Olivier Andréoletti; Pierre-Louis Toutain
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

6.  Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum.

Authors:  Marc O Anderson; John Sherrill; Peter B Madrid; Ally P Liou; Jennifer L Weisman; Joseph L DeRisi; R Kiplin Guy
Journal:  Bioorg Med Chem       Date:  2005-10-10       Impact factor: 3.641

7.  Residues surrounding the glycosylphosphatidylinositol anchor attachment site of PrP modulate prion infection: insight from the resistance of rabbits to prion disease.

Authors:  Rebecca M Nisbet; Christopher F Harrison; Victoria A Lawson; Colin L Masters; Roberto Cappai; Andrew F Hill
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

8.  Multimodal small-molecule screening for human prion protein binders.

Authors:  Andrew G Reidenbach; Michael F Mesleh; Dominick Casalena; Sonia M Vallabh; Jayme L Dahlin; Alison J Leed; Alix I Chan; Dmitry L Usanov; Jenna B Yehl; Christopher T Lemke; Arthur J Campbell; Rishi N Shah; Om K Shrestha; Joshua R Sacher; Victor L Rangel; Jamie A Moroco; Murugappan Sathappa; Maria Cristina Nonato; Kong T Nguyen; S Kirk Wright; David R Liu; Florence F Wagner; Virendar K Kaushik; Douglas S Auld; Stuart L Schreiber; Eric Vallabh Minikel
Journal:  J Biol Chem       Date:  2020-07-28       Impact factor: 5.157

9.  Inhibition of RNA recruitment and replication of an RNA virus by acridine derivatives with known anti-prion activities.

Authors:  Zsuzsanna Sasvari; Stéphane Bach; Marc Blondel; Peter D Nagy
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

10.  Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases.

Authors:  Jian-Hua Zhao; Hsuan-Liang Liu; Hsin-Yi Lin; Chih-Hung Huang; Hsu-Wei Fang; Shiao-Shing Chen; Yih Ho; Wei-Bor Tsai; Wen-Yih Chen
Journal:  Perspect Medicin Chem       Date:  2007-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.